In this study, the authors show that the rare codons of KRAS, yielding low oncogene expression, can be overcome to drive resistance to anti-EGFR therapy in CRC through upregulation of global translation or through selection of more potent KRASQ61mutations. This evidence concerns the gene EGFR and colorectal carcinoma.